Evidence map›Paper›PMID 42820802›Full record

ArticleInvestigative ophthalmology & visual science2026

Establishment of Uveal Melanoma Patient-Derived Organoids Using an Air-Liquid Interface System for Translational Research.

Leticia Ussem, Karin U Loeffler, Verena Tischler, Marieta Toma, Natalie Pelusi, Frank G Holz, Anne Gulbins, Daniela Süsskind, Roberta Noberini, Tiziana Bonaldi and 1 more

Abstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Leticia UssemUniversity of Bonn, University Hospital Bonn, Department of Ophthalmology, Bonn, Germany.
Karin U LoefflerUniversity of Bonn, University Hospital Bonn, Department of Ophthalmology, Bonn, Germany.
Verena TischlerInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Marieta TomaInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Natalie PelusiInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Frank G HolzUniversity of Bonn, University Hospital Bonn, Department of Ophthalmology, Bonn, Germany.
Anne GulbinsUniversity of Bonn, University Hospital Bonn, Department of Ophthalmology, Bonn, Germany.
Daniela SüsskindDepartment of Ophthalmology, University Hospital Tübingen, Tübingen, Germany.
Roberta NoberiniDepartment of Experimental Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Tiziana BonaldiDepartment of Experimental Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Martina C Herwig-CarlUniversity of Bonn, University Hospital Bonn, Department of Ophthalmology, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, with a unique genetic and epigenetic profile and a high metastatic risk. The lack of experimental models to replicate tumor biology, including its epigenetic landscape, limits progress in translational research. Recently, patient-derived organoid (PDO) models have emerged as a promising tool for the modeling of various tumors, including UM. This study aims to establish an air-liquid interface (ALI) PDO culture system for UM, evaluate its similarity to the primary tumors, and assess its utility for drug screening. Methods: Fresh and cryopreserved tissue samples from primary UM of 5 patients were cultured using a protocol previously validated for other malignancies. The subsequent characterization of the ALI PDOs included histologic and immunohistochemical evaluation, DNA and RNA sequencing, and histone posttranslational modification (HPTM) analysis. The model's drug-screening potential was evaluated by treating ALI PDOs with the histone deacetylase inhibitor quisinostat and comparing their responses with those of controls. Results: UM ALI PDOs were successfully established and retained their original tumors' immunophenotype and genetic variants. Gene expression profiling revealed similarities between PDOs and primary tumors, with main differences consisting of microenvironment-related signals. Epigenetic analysis confirmed that the overall HPTM landscape remained preserved. Treatment of the PDOs with quisinostat led to transcriptional reprogramming and the expected epigenetic response, with increased acetylation marks. Conclusions: The UM ALI PDO model recapitulates the genetic and epigenetic features of primary UM and holds promise as a platform for future molecular studies and the testing of personalized therapy strategies.

Indexed as

MelanomaOrganoidsTranslational Research, BiomedicalUveal NeoplasmsAgedFemaleHistone Deacetylase InhibitorsHumansImmunohistochemistryMaleMiddle AgedTumor Cells, CulturedUveal MelanomaHistone Deacetylase Inhibitors

Identifiers

PMID42820802
PMCPMC13648566

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.